Preclinical Data and Mechanism of Action

Living cells consist of charged or polar molecules and ions and thus are responsive to electrical fields and currents. Electric activity of cells plays a key role in many essential biological processes including cell division. Cellular processes can be influenced by electric fields. The overall effect will depend upon the magnitude of the potential difference between the electrodes (field intensity) and the frequency: at very low frequencies (<1 kHz) excitable cells such as neurons or myocytes will be depolarized.1 Cardiac pacemakers or deep brain stimulators work in this range of frequency. At very high frequencies (>MHz), heat is generated in the tissues due to dielectric loss. This property is mainly used for radiofrequency ablation or diathermy treatments.2 The alternating frequency of electrical fields at intermediate frequencies (range, 10–1000 kHz) is too fast to induce cell depolarization and induces no or only minimal heat by dielectric loss. In the past, these frequencies were considered to have no interaction with biological processes.3 Nevertheless, a number of effects have been observed in biological tissues such as microscopic particle alignment,4 cell rotation,5 and transient pore formation in cell membranes.6 At low intensities (2V/cm) and intermediate alternating frequencies (between 100–300 kHz), Kirson and Palti et al. demonstrated a specific inhibiting effect on cell division in cancer cell culture models.7

Tumor treating fields (TTFields) are alternating, low-intensity, intermediate frequency electric fields that aim to disrupt cell division and inhibit tumor growth. In initial experiments, exposure of a variety of tumor cell lines to TTFields was shown to exert a profound growth inhibitory effect by inducing cell cycle arrest and apoptosis, while no effect was induced on non-dividing cells.7 These in vitro observations could also be confirmed in vivo in mice and rabbit tumor models.8 Further studies demonstrated that the growth inhibitory effect is largely mediated by interference on the mitotic spindle apparatus. TTFields will target proteins with large dipole moments (ie, septins and the spindle microtubules, components essential in the metaphase and anaphase stages of the mitotic cycle for separation and equal distribution of chromosomes).9,10 Furthermore, inhibition of the polymerization of microtubules interferes with proper assembly of the mitotic spindle apparatus. In telophase, during cytokinesis the hourglass shape taken by the daughter cells that are about to separate induces a nonuniform electric field that is strongly enhanced at the level of the furrow region (→ fig. 1). This results in dielectrophoretic forces that may attract charged molecules from the cytosol and compromise normal cytokinesis.7 The antitumoral effect results from disruption of the microtubular assembly during mitosis, blocking formation of the mitotic spindle apparatus and blocking separation of the 2 daughter cells.9 This effect also results in abnormal chromosomal segregation and reduced clonogenic potential of the cell's progeny.10

Received 1 May 2016; accepted 11 July 2016
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

For commercial re-use, please contact journals.permissions@oup.com.
Animal models of various tumors, including glioblastoma (GBM), non–small cell lung cancer, pancreatic cancer, and malignant melanoma confirmed the inhibition of tumor growth or metastatic seeding when externally applied TTFields were delivered at the appropriate frequencies. As an example, an experimental model of rats with intracranially inoculated GBM cells treated with TTFields at a frequency of 200 kHz over 6 days showed smaller tumors compared with untreated rats. The inhibitory effect was significantly increased when 2 or more, rather than 1 field directions were used. Importantly, synergistic antitumor activity was demonstrated when TTFields were applied in conjunction with cytotoxic chemotherapy with paclitaxel, doxorubicin, cyclophosphamide, or dacarbazine (DTIC).

In summary, TTFields will block the mitotic cell cycle, in particular during metaphase, anaphase, and telophase. This will result in cell cycle arrest or delay in cell division and interfere with organelle assembly, particularly the spindle apparatus (fig. 1 C). The consequences are inadequate cell division and unequal chromosome distribution. Ultimately, cells will die in apoptosis. In order to have an optimal treatment effect, the field intensity and frequency needs to be adapted to the tumor type and cell properties (eg, cell size). The optimal frequency to maximize the antitumor effect is inversely correlated with cell size and when the incident angle of the electrical field is perpendicular to the mitotic plate.

As the cell division may occur at any time, prolonged exposure to the electrical fields is required for maximal effect. For the delivery of TTFields, a portable and battery-powered device has been developed (fig. 2). The electric field is applied to the brain through 4 transducer arrays with 9 insulated electrodes each and continuous temperature sensing fixed to the patient’s shaved scalp.

Clinical Experience:

**Glioblastoma as a Proof of Concept Model**

In the very first clinical application, TTFields treatment was applied to patients with cutaneous metastases of melanoma or breast cancer. Tumor shrinkage or even complete disappearance was demonstrated. However, metastatic cancer is a systemic disease, thus most effects of application of TTFields would be expected to be seen in diseases or situations where primarily locoregional control is warranted. Primary brain tumors—and notably glioma—rarely metastasize; recurrence in the brain is the predominant cause of treatment failure and was chosen as the first disease in which the effect of TTFields could be investigated prospectively.
In a computational model, the optimal frequency of TTFields for GBM was found to be in the range of 200 kHz. The field strength should be ≥ 1 V/cm. These TTFields are able to penetrate into the deep brain tissue from the surface of the scalp. The computational model also revealed inhomogeneous fields with intensification of the field strength near the ventricles as a result of the high conductivity of the cerebrospinal fluid. Necrotic areas and edematous regions also showed high conductivity of the TTFields. In contrast, areas with high cellularity showed lower conductivity. 

Following the demonstration of feasibility in a small pilot trial, the clinical merits of this innovative cancer treatment were evaluated in 2 pivotal randomized trials in recurrent (EF-11) and newly diagnosed (EF-14) GBM. In our summary, herein we always refer to the results of the intent-to-treat population (ITT); for details on the predefined per protocol populations, the reader is kindly directed to the respective original publications. 

TTFields in Recurrent Glioblastoma

The EF-11 Trial

For this trial, GBM patients with progressive or recurrent disease after initial treatment with radiotherapy and TMZ chemotherapy were eligible. Patients may have received several lines of prior chemotherapy. A total of 237 patients were then randomized 1:1 to either the novel TTFields therapy (120 patients) or to the best available treatment (117 patients) according to the local oncologist’s best choice (active control, fig. 3A). The primary endpoint of the trial was OS. Patients’ median age was 54 years, with a median KPS of 80% (range, 50–100%). Eighty-eight percent of patients had received 2 or more lines of prior chemotherapy including prior bevacizumab in 18% of patients. With a median survival of only 6.6 and 6.0 months in the TTFields and the control arm, respectively (hazard ratio: 0.86 [95% CI, 0.66–1.12], P=0.27) and a 1-year survival rate of only 20% in both groups, the trial failed to demonstrate superiority over “established” or commonly used chemotherapy
regimens. The median duration of TTFields administration was only 2.3 months (95% CI, 2.1–2.4) with tumor progression as the primary reason for discontinuation of treatment. Still it showed objective responses with TTFields alone in 14% of patients compared with 9.6% in the control arm. The study demonstrated safety and feasibility of TTFields in a large multicenter setting.

The design and conduct of the EF-11 trial had some inherent limitations: numerous prior treatment lines were allowed and led to a heterogeneous patient population. More than 40% of patients were included after the third recurrence, including many patients who had failed prior bevacizumab therapy. Thus, most patients suffered from very advanced disease and had only few available treatment options and limited life expectancy. In the absence of a commonly accepted standard treatment for recurrent GBM, the control patients were to receive the best available systemic therapy according to the current local practice. The heterogeneity of treatments prescribed to the control patients reflects this fact: about one-third of the control patients received bevacizumab alone or in combination, 25% nitrosoureas, and 11% re-exposure to TMZ. A number of patients were discontinued from TTFields therapy very early (after <1 month of therapy), presumably due to absence of a treatment response (rather than true tumor progression) based on skepticism of the investigators. It is known that TTFields take a prolonged period of time until its effects can be clinically demonstrated or that delayed responses may occur after initial radiological tumor growth; thus, some patients may have discontinued TTFields treatment prematurely.

Based on the results of the EF-11 trial, the US Food and Drug Administration (FDA) felt that these results provided reasonable
assurance that the benefits of TTFields outweigh its risks when administered as monotherapy in place of standard medical therapy and therefore approved TTFields in 2011 (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm).

TTFields in Daily Practice: PriDE Dataset

After FDA approval, TTFields became commercially available in the United States, and Mrugala et al summarized the daily practice experience on 457 patients treated at 91 US institutions (Patient Registry Dataset; PriDE). Interestingly, patients’ age and performance status were similar in this dataset and in the EF-11 trial; however, treatment with TTFields was initiated much earlier in the course of the disease. One-third of patients were treated at first recurrence (n=152), whereas patients in the TTFields/TMZ group and in 41% of the control TMZ group. The median time from end of radiation therapy to randomization was 36 and 38 days in the TTFields and control groups, respectively. The median time from randomization to initiation of TTFields was 5 days. Median time from diagnosis of GBM to randomization was 3.8 months in both groups (ranges, 2.0–5.7 and 1.4–5.7 months in the treatment and control groups, respectively). Of note, 53% of patients were randomized after initiation of the first cycle of TMZ (as allowed by the protocol). Per protocol, TTFields treatment was continued up to the second progression in two-thirds of the patients; the median duration of treatment with TTFields was 9 months (range, 1–58 mo). Three-quarters of patients receiving treatment with TTFields were adherent to therapy as prescribed (ie, wearing the device ≥ 18 hours per day on average during the first 3 treatment months) (n=157/210).

At a prespecified interim and futility analysis to be performed once the first 315 randomized patients reached a minimum follow-up of 18 months, a significant improvement in progression-free and overall survival was seen; consequently the independent data monitoring committee recommended that the trial be terminated early for success and that patients be allowed to cross over to the TTFields arm. In the interim analysis, the ITT median PFS was increased by 3.1 months in the TTFields group with a median PFS of 7.1 months (95% CI, 5.9–8.2 mo) compared with 4.0 months (95% CI, 3.3–5.2 mo) in the control group (HR, 0.62 [98.7% CI, 0.43–0.89]; P=.001). As a direct consequence, patients in the control group received a median of 4 cycles of TMZ (range, 1–24), whereas patients in the TTFields group received a median of 6 cycles (range,1–26) of TMZ. Median OS from randomization (ITT) was 19.6 months (95% CI, 16.6–24.4 mo) in the TTFields plus TMZ group compared with 16.6 months (95% CI, 13.6–19.2 mo) in the TMZ control group (HR: 0.74 [95% CI, 0.56–0.98]; P = .03). The percentage of patients alive at 2 years following enrollment was 43% in the TTFields/TMZ group and 29% in the TMZ alone group (P=.006)17 (fig. 4). At first progression, 67% of patients in the TTFields/TMZ group received a second-line therapy compared with 57% of patients in the TMZ control group. The type of salvage chemotherapy offered was balanced between the 2 groups: about 40% of second-line therapies included bevacizumab and about 40% nitrosoureas.

Preliminary subgroup analyses showed that the positive effect observed on PFS and OS by the addition of TTFields was not restricted to any subgroup of patients: in particular for age subgroup, performance status, MGMT methylation status, nor extent of resection was predictive for a better treatment response.
effect. However, the sample size of the interim dataset may not be large enough to identify meaningful subgroups, and detailed subgroup analyses are to be performed on the final and validated dataset. Due to the 2:1 randomization, the control arm comprised only 105 patients, which limited the ability to perform formal subgroup analyses. In the final dataset, the control group will comprise 229 patients. Before publication of the interim analysis, the overall dataset of 695 randomized patients was statistically scrutinized. It was concluded that the results are unlikely to change substantially once the whole dataset reaches a mature follow-up (see supplemental material, reference 17). In October 2015, the FDA approved TTFields for use in newly diagnosed GBM patients.

**Toxicity, Support, and Quality of Life with TTFields**

Toxicity related to TTFields therapy consisted, by the nature of this treatment, mainly of local skin irritation. This is usually mild, self-limiting, easily manageable with local application of steroid-containing ointments, and may require an occasional treatment break for a few days. In the EF-11 trial, skin toxicity was reported in 16% of patients (grade 3 in only 2%). In the EF-14 trial for newly diagnosed GBM patients, where the treatment exposure was longer than that for recurrent disease, grades 1 and 2 skin reactions were reported in 43% of patients. Severe (grade 3) reactions were again seen in only 2% of patients. Examples of allergic contact dermatitis, irritant contact dermatitis, folliculitis, and erosions are shown in fig. 5.

Importantly, when compared with TMZ maintenance treatment alone, the addition of TTFields did not result in any modification of the overall incidence, severity, and distribution of side effects in patients with newly diagnosed GBM. The incidence of seizures was identical in both treatment groups (7% in the TTFields group vs 8% in the control group). Some nonspecific adverse effects including nervous system disorders such as grade 1–2 headache (21% in the experimental group vs 14% in patients with TMZ alone), mild anxiety, confusion, insomnia, and headaches were reported more frequently in the patients treated with TTFields plus TMZ and occurred mainly at the time of therapy initiation.

Given the need for continuous and long-term use of the TTFields device, the quality of life of patients has been a concern. In the EF-11 trial, there were no differences in global health and social functioning between patients treated with TTFields or chemotherapy. The incidence of seizures was identical in both treatment groups (7% in the TTFields group vs 8% in the control group). Some nonspecific adverse effects including nervous system disorders such as grade 1–2 headache (21% in the experimental group vs 14% in patients with TMZ alone), mild anxiety, confusion, insomnia, and headaches were reported more frequently in the patients treated with TTFields plus TMZ and occurred mainly at the time of therapy initiation.
data showed identical scores at baseline and at 12 months for patients in the treatment and control groups at the levels of cognitive, emotional, physical, and social functioning. Moreover, the global health status showed an improvement at 3 and 6 months in comparison with baseline for patients treated with TTFields and TMZ, whereas patients in the control group showed a decrease in global health status over the same time period.

**Discussion**

More than a decade ago, in vitro and in vivo experiments in tumor cell lines and in mouse, rat, and rabbit tumor models have demonstrated antitumor activity of low-intensity, intermediate-frequency alternating electric fields. Dividing cells are arrested in metaphase and anaphase, assembly and function of the mitotic spindle are perturbed, and cells ultimately undergo apoptosis. However, in order to translate these findings into a clinically useful treatment, certain conditions must be met: (1) TTFields need to be delivered in a continuous manner to achieve the expected cytotoxic effect; (2) TTFields can only be applied to certain areas of the body, and this (3) requires the possibility to affix transducer arrays to the skin of the patient over the area of the tumor. As GBM is a disease that remains confined to the CNS and the scalp offers an easy application site for long-term use of transducer arrays, it appeared to be the ideal candidate to serve as a proof of concept demonstration of TTFields.

Two pivotal randomized trials have been reported to date. In recurrent disease, the trial has not demonstrated improved outcome compared best physicians’ choice chemotherapy. However, TTFields when administered as part of the initial treatment in newly diagnosed patients showed a consistent prolongation of both PFS and OS (hazard ratio for death HR: 0.74 (95% CI, 0.56–0.98). Giving TTFields early in the disease course allows for prolonged exposure, and the in vitro observed synergy with TMZ may further enhance its efficacy. The median treatment duration in recurrent disease was only 2.3 months compared with 9 months in newly diagnosis GBM. Still, TTFields alone in recurrent disease have shown objective responses in 14% of patients, consistent or even numerically higher than that observed in other trials using alkylating agent chemotherapy with lomustine or TMZ.

In the PriDE dataset reflecting routine clinical use of the device, patients who received TTFields at first recurrence were treated for a median of 6.2 months and had a median survival of 20 months, comparing favorably with recent trial results investigating other novel agents. However, a strong selection bias and inclusion of patients with pseudoprogression after initial TMZ chemoradiotherapy cannot be ruled out in this uncontrolled routine practice patient population.

The best results with this novel treatment modality have been achieved when TTFields were administered early in the disease course in combination with standard maintenance TMZ therapy, similar to that shown 10 years ago when TMZ was added to standard radiotherapy.

It may be scientifically regrettable that the trial had to be open label and did not include a double-blinded control group. However, a sham device would neither be practically feasible (some heating of the electrodes is inevitable; technically
savvy patients would rapidly figure out whether there is any current flowing, nor acceptable for patients, caregivers, and ethics committees given the perceived burden of shaving the scalp and replacing transducer arrays every 3 days. Whereas some placebo effect might be expected on subjective endpoints, such as quality of life or cognitive function, it is difficult to envision an effect on objective endpoints such as OS or PFS (especially when progression was determined by blinded central radiologists). Requiring a placebo or sham device would also mean a paradigm shift in conducting clinical trials with survival endpoints in oncology. Sham radiation therapy would be required for RT trials, and a placebo control would only be feasible for agents that have rare and mild toxicities.

Indeed, patients receiving TTFIELD therapy received some additional assistance by the technical support team providing the TTFIELDs device and arrays. However, this support was on average limited to 1 visit per month, and 1–2 extra visits or contacts at the initiation of treatment. Most patients became rapidly independent and self-proficient with the device; on average, there was a median of 1.12 visits per patient and month of treatment (range, 0.5–4 visits per month).

It is highly unlikely that this additional technical support would translate into a 3-month prolongation of median survival, which is in the range of the benefit seen with the introduction of TMZ. In a contemporary randomized open-label non-placebo-controlled trial, patients in the experimental arm received twice weekly i.v. administration of citengidite. Still, this did not translate into any benefit in outcome (hazard ratio for death: 1.02; 95% CI 0.81–1.29).

It might have been possible that the control arm in EF-14 performed exceptionally poorly. We thus scrutinized the data and compared the performance of the control arms of contemporary trials. The patient characteristics of both the TTFields and control groups were comparable with other clinical trials for newly diagnosed GBM patients in respect to all known prognostic factors (distribution of age, performance status, extent of resection, MGMT status).

One important difference in the EF-14 trial compared with many other reports is that patients were randomized only after the end of chemoradiotherapy, and for most patients the first cycle of maintenance TMZ had already been started at time of randomization. This implies that all patients with early tumor progression during the concomitant radiation and TMZ part of the treatment were excluded from this trial. On the other hand, the 3.8 months from diagnosis to randomization will need to be added to survival times in order to have an estimate of the individual patients' effective outcome. The PFS of 4.0 months (from randomization) observed in the control group of the EF14 trial is numerically shorter (likely due to the independent imaging review and assessment of progression) but overall comparable to the observed PFS of 5.5 months observed in the RTOG 0525 trial, a trial that also randomized patients only after completion of the concomitant radiochemotherapy part of treatment. Moreover, in both trials, the OS was identical at 16.6 months for the control groups. It is therefore unlikely that the benefit observed in the treatment group of the EF14 trial can be attributed to patient selection and a poor outcome of patients in the control arm.

For many experts in neuro-oncology who were not involved in the trial, the most important criticism to TTFIELDs was the requirement for patients to wear a device and their presumed stigmatization. Having to shave the scalp is indeed a psychological barrier, although in oncology, for decades we have been using cytotoxic agents that are inducing complete hair loss of all body hair and not only the scalp. In our experience, patients and families rapidly adapt to wearing the device and are able to continue their regular activities including work and even sports. Preliminary analysis of the self-reported quality of life data from the EF14 trial showed identical scores for both groups at baseline and at 12 months for patients in the treatment and control group at the levels of cognitive, emotional, physical, and social functioning. To reduce some of the burden of therapy, a second generation of the TTFIELDs device with a reduction in size and weight by about 50% compared with the device used in the EF-11 and EF-14 devices has been developed.

Conclusions & Future Perspectives

The results of the randomized phase III EF-14 trial provide level 1 evidence that alternating electric fields are able to positively impact tumor growth and significantly extend survival in GBM. As a logical consequence, TTFIELDs were approved by the FDA for newly diagnosed GBM in October 2015. Nevertheless, numerous questions remain and need to be addressed, both within the EF-14 trial and in future studies; Notably, it will be essential to be able to (1) identify the patients most likely to respond to TTFIELDs therapy, (2) further elucidate the mechanism of action of TTFIELDs, (3) elucidate the mechanisms of resistance to and failure of TTFIELDs therapy, and (4) elucidate the pattern and predictors of response.

In GBM we will need to integrate this novel treatment approach in the current standard of care, and ultimately novel clinical trials will also need to integrate TTFIELDs (at least in the control arm). A pragmatic alternative is to stratify patients for the use of TTFIELDs as part of their standard of care in both the standard and experimental arms.

TTFIELDs is a locoregional treatment, and extending its use to other tumor types and metastatic disease is most promising in clinical situations where locoregional disease control is key for quality of life. The excellent compatibility between TTFIELDs and various chemotherapeutic agents has already been demonstrated, not only in GBM patients in the EF-14 trial but also in lung cancer patients. TTFIELDs may also be synergistic with immune therapy approaches. Senovilla et al showed that cells that cannot undergo mitotic exit show hallmarks of immunogenic cell death where the immune system induces a strong response against the dying cells.

The positive results of the EF-14 demonstrate that neuro-oncology can lead the way to innovation. The results of the EF-14 trial pave the way to investigate the role of alternating electrical fields in other oncologic situations amenable to locoregional treatment such as brain metastases, ovarian carcinoma, mesothelioma, or pancreatic tumors. These trials are currently ongoing. For instance, in pancreatic cancer, TTFIELDs therapy, in addition to gemcitabine resulted in a median PFS of 8.3 months (CI, 3–10.3 mo) in a phase 2 study.
### Table 2. Ongoing clinical trials in solid tumors

| Disease, indication | Name of trial | Protocol description | # Pts | Phase | Endpoints | Sponsor | NCT# |
|---------------------|---------------|----------------------|-------|-------|-----------|---------|------|
| Recurrent GBM       | Recurrent GBM | EF-26 (Japan)        | 30    | IV    | Incidence & severity of treatment-related skin & CNS disorders: secondary: 1-y survival; PFS6mo | Novocure (EF-26) (Japan) | NA (Japan) | NCT01925573 |
|                     | Recurrent GBM | Optune™ + bev & hypofractionated stereotactic RT in bev-naive GBM | 27    | I     | Safety    | U Maryland | NCT02348255 |
|                     | Recurrent GBM | Optune™ with bev & carmustine in treating patients with GBM in first relapse | 20    | II, single arm | Safety, PFS, PFS6, OS | UC Davis | NCT02663271 |
|                     | Recurrent GBM | Multicenter study of TTFields & pulsed bev | 25    | II, single arm | PFS, QoL questionnaires | Univ of Florida | NCT01954576 |
|                     | Recurrent GBM | Phase 2 study of TTFields, enhanced by genomic analysis to identify a genetic signature for response | 30    | II, pilot | Efficacy; QoL | Washington Univ School of Medicine | NCT01894061 |
|                     | Recurrent GBM | Optune™ with bev in GBM | 40    | II, open label | Safety & Efficacy | Case Comprehensive Cancer Ctr, Cleveland, OH | NCT02441322 |
|                     | Newly diagnosed & recurrent GBM | High Resolution MRI 7 MRS to Evaluate Therapeutic Response to Novo-TTF in Newly & Recurrent GBM | 10    | II     | RR, using SOC MRIs | Univ of Penn | NCT02441322 |
|                     | Newly diagnosed GBM | A Phase II Study of Optune™ in combo with BEV & TMZ in pts with newly diagnosed unresectable GBM | 46    | II, single arm | Safety & efficacy | Carolinas Healthcare System | NCT02343549 |
| Low grade gliomas   | Newly diagnosed low grade gliomas | Phase II study of Optune™ ± TMZ in pts with Low-Grade Gliomas | 42    | II, single arm | ORR, Secondary- PFS | UCSD | NCT02507232 |
| Disease, indication | Name of trial | Protocol description | # Pts | Phase | Endpoints | Sponsor | NCT# |
|---------------------|---------------|----------------------|-------|-------|-----------|---------|------|
| Meningioma          | Pilot Study of Optune™ for Recurrent Atypical & Anaplastic Meningioma | TTFields | 21    | Pilot | Safety & Efficacy | MSKCC | NCT01892397 |
| Brain metastases    | COMET         | Maintenance TTFields vs supportive care - best SOC alone (after completion of standard local therapy) | 60    | II, randomized | Time to local/ distant progression | Novocure (EF-21) EU | NCT01755624 |
| NSCLC with 1–10 brain metastases | METIS | Radiosurgery ± TTFields | 240   | III, randomized | Time to first cerebral progression | Novocure (EF-25) Global | Pending FDA IDE approval |
| Solid tumors        | PANova        | + gem or gem/nab-paclitaxel | 40    | III/II, 2-cohorts | Safety; feasibility; prelim efficacy | Novocure (EF-20) EU | NCT01971281 |
| Recurrent ovarian carcinoma | INNOVATE | Concomitant with weekly paclitaxel Pemetrexed & cisplatin or carboplatin ± TTFields | 30    | III/II pilot study | Safety, toxicity, feasibility & prelim efficacy | Novocure (EF-22) EU | NCT02244502 |
| Pleural mesothelioma | STELLAR       | Pemetrexed & cisplatin or carboplatin + TTFields | 80    | II, open label | Safety & efficacy (OS) | Novocure (EF-23) EU | NCT02397928 |
| Front-line treatment for advanced NSCLC with squamous histology | LUNAR | Combination chemotherapy ± TTFields | 300   | pivotal open-label randomized | Protocol in preparation | Novocure (EF-24) Global | NA |

NCT#: ClinicalTrials.gov Identifier, Novocure; Novocure Ltd, manufacturer of TTFields (Optune™) device
Abbreviations: BCNU, carmustine; bev, bevacizumab (Avastin®); EU, European Union; GBM, glioblastoma; Gem, gemcitabine; MSKCC, Memorial Sloan-Kettering Cancer Center; nab-paclitaxel; albumin-bound paclitaxel (Abraxane®), NSCLC, non–small cell lung cancer; OS, overall survival; PFS, progression-free survival; EU
on 20 patients. The partial response rate was 30% and another 30% stable disease. The median OS for all patients was promising for this disease at 14.9 months. It was not reached in patients with locally advanced disease, and 8.3 months (CI, 4.3–14.9 mo) for patients with metastatic disease with 1-year survival rates of 86% in locally advanced patients and 40% in patients with metastatic disease. If those trials confirm the positive effects observed in GBM patients, a truly new cancer treatment modality has been born and will find multiple useful indications alone or in combination with other established or new treatments.

Conflict of Interest Statement. The authors declare no conflict of interest relevant to this review article.

Advisory details: Roger Stupp has served as the coordinating principal investigator on Novocure-sponsored clinical trials but did not receive any personal or institutional fees from Novocure. Management details: Roger Stupp serves as the president of the European Organisation for Research and Treatment of Cancer (EORTC). EORTC conducts academic clinical trials in a variety of tumor types, including brain tumors. The following authors declare paid consulting conflicts as described here: Roger Stupp has served on non-remunerated advisory boards for Novocure Ltd. Andreas Hottinger has served on advisory boards, fees (when applicable) to the institution. Roger Stupp and Andreas Hottinger have received travel support for scientific presentations of the trial results at academic meetings.

References

1. Patli Y. Stimulation of internal organs by means of externally applied electrodes. J Appl Physiol. 1966;21(5):1619–1623.
2. Storm FK, Morton DL, Kaiser LR et al. Clinical radiofrequency hyperthermia: a review. Natl Cancer Inst Monogr. 1982;61:343–350.
3. Polk C, Postow E. Handbook of biological effects of electromagnetic fields. Boca Raton, FL: CRC Press; 1995.
4. Takashima S, Schwan HP. Alignment of microscopic particles in electric fields and its biological implications. Biophys J. 1985;47(4):513–518.
5. Holzapfel C, Vienken J, Zimmermann U. Rotation of cells in an alternating electric field: theory and experimental proof. J Membr Biol. 1982;67(1):13–26.
6. PawlowskiP, Szutowicz J, Marszalek P, Fikus M. Bioelectrotherapeutical model of the cell. S. Electrodestruction of cellular membrane in alternating electric field. Biophys J. 1993;65(1):541–549.
7. Kirson ED, Gurvich Z, Schneiderman RS et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288–3295.
8. Kirson ED, Giladi M, Gurvich Z et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633–640.
9. Gera N, Yang A, Holtzman LS et al. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):e0125269.
10. Giladi M, Schneiderman RS, Valoshin T et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015;5:18046. doi:10.1038/srep18046.
11. Giladi M, Schneiderman RS, Porat Y et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology. 2014;14(1):54–63.
12. Kirson ED, Dbaly V, Tovarys F et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152–10157.
13. Giladi M, Weinberg U, Schneiderman RS et al. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014;41 Suppl 6:535–41.
14. Kirson ED, Schneiderman RS, Dbaly V et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.
15. Wenger C, Salvador R, Bossor PJ, Miranda PC. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study. Phys Med Biol. 2015;60(18):7339–7357.
16. Stupp R, Wong ET, Kanner AA et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–2202.
17. Stupp R, Taillibert S, Kanner AA et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015;314(23):2535–2543.
18. Mrugala MM, Engelhard HH, Dinh Tran D et al. Clinical practice experience with NovoTTF-100A system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014;41 Suppl 6:54–513.
19. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
20. Tophoorn MJ, Claassens L, Aaronson NK et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033–1040.
21. Lacouture ME, Davis ME, Elzinga G et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41 Suppl 4:51–14.
22. Zhu JJ, Pannullo S, Mehdorn M et al. ACTC-35, Quality of life, cognitive function and functional status in the EF-14 trial. Neuro Oncol. 2015;17:v1–v9.
23. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168–1174.
24. Batchelor TT, Mulholland P, Neyns B et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–8.
25. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–593.
26. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
27. Chvetzoff G, Tannock IF. Placebo effects in oncology. J Natl Cancer Inst. 2003;95(1):19–29.

28. Stupp R, Hegi ME, Gorlia T et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100–1108.

29. Gilbert MR, Wang M, Aldape KD et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091.

30. Pless M, Droege C, von Moos R et al. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81(3):445–450.

31. Senovilla L, Vitale I, Martins I et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684.

32. Rivera F, Gallego J, Guillen C et al. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. J Clin Oncol. 2016;34(suppl; abstr 4125).